Chile Gastric Cancer Treatment Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Published Report
  • Jan 2022
  • Country Level
  • 350 Pages
  • No of Tables: 12
  • No of Figures: 40

Chile Gastric Cancer Treatment Market, By Type (Adenocarcinoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Lymphoma and Others), Stages (Stage III, Stage II, Stage IV, Stage I and Others), Treatment (Chemotherapy, Targeted Therapy, Immune Checkpoint Inhibitors, and Others), Route of Administration (Parenteral, Oral, and Others), End User (Hospitals, Specialty Clinics, Research & Academic Institutes and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others). Industry Trends and Forecast to 2029. 

Market Analysis and Insights : Chile Gastric Cancer Treatment Market

Chile gastric cancer treatment market is expected to gain significant growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyzes that the market is growing with a CAGR of 7.7% in the forecast period of 2022 to 2029 and is expected to reach USD 23.75 million by 2029. Rising cases of gastrointestinal tumors, lymphoma, and adenocarcinoma have increased the demand for medication and treatment are expected to drive the gastric cancer treatment market growth.

Gastric cancer is a disease in which malignant (cancer) cells form in the lining of the stomach. The age, diet, and stomach disease can affect the risk of developing gastric cancer. Symptoms of gastric cancer include indigestion and stomach discomfort or pain.

The wall of the stomach is made up of five layers of tissue. From the innermost layer to the outermost layer, the layers of the stomach wall are: mucosa, submucosa, muscle, subserosa (connective tissue), and serosa. Gastric cancer begins in the mucosa and spreads through the outer layers as it grows. Stomach cancers tend to develop slowly over many years. Before a true cancer develops, pre-cancerous changes often occur in the inner lining (mucosa) of the stomach before the complete development of the cancer. These early changes rarely cause symptoms, so they often go undetected. Cancer’s development in different sections of the stomach can cause different symptoms and tend to have different outcomes. The cancer’s location can also affect treatment options.

Rising incidence of gastric cancers and increasing healthcare expenditure are expected to boost the growth of market across Chile.

Chile Gastric Cancer Treatment Market

Chile Gastric Cancer Treatment Market Scope and Market Size

Chile gastric cancer treatment market is segmented based on type, stages, treatment, route of administration, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of type, the Chile gastric cancer treatment market is segmented into adenocarcinoma, gastrointestinal stromal tumor, carcinoid tumor, lymphoma, and others. In 2021, adenocarcinoma segment is expected to dominate the market owing to increasing prevalence of this specific gastric cancer type in Chile.
  • On the basis of stages, the Chile gastric cancer treatment market is segmented into stage III, stage II, stage IV, stage I, and others. In 2022, stage III segment is expected to dominate the market because of the high drug consumption in this particular stage.
  • On the basis of treatment, the Chile gastric cancer treatment market is segmented into chemotherapy, targeted therapy, immune checkpoint inhibitors, and others. In 2022, chemotherapy segment is expected to dominate the market due to the overall survival rate and low recurrence rate of gastric cancer associated with this treatment.
  • On the basis of route of administration, the Chile gastric cancer treatment market is segmented into parenteral, oral, and others. In 2022, parenteral segment is expected to dominate the market as it is the most efficient way of treating cancer. Moreover, various treatments are available in injectable form.
  • On the basis of end user, the Chile gastric cancer treatment market is segmented into hospitals, specialty clinics, research & academic institutes, and others. In 2022, hospitals segment is expected to dominate the market as it provides patients with the best healthcare services. Hospitals in developed and developing countries are highly demanding for advanced cancer treatment due to the rising healthcare concerns of the patients.
  • On the basis of distribution channel, the Chile gastric cancer treatment market is segmented into hospital pharmacy, retail pharmacy, and others. In 2022, hospital pharmacy segment is expected to dominate the market as they are the primary source of various drugs recommended by the oncologist for gastric cancer treatment and brand satisfaction.

Chile Gastric Cancer Treatment Market Country Level Analysis

Chile gastric cancer treatment market is analyzed and market size information is provided by the type, stages, treatment, route of administration, end user, and distribution channel as referenced above.

The country covered in the Chile Gastric cancer treatment market report is Chile.

Targeted products segment in Chile is expected to grow with the highest growth rate in the forecast period of 2022 to 2029 owing to increasing drug approvals and its ability to be administered as a standalone drug especially in certain stages.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Chile brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Growing Strategic Activities by Major Market Players to Enhance the Awareness for Gastric cancer is Boosting the Market Growth

The Chile gastric cancer treatment market also provides you with detailed market analysis for every country growth in a particular market. Additionally, it provides detailed information regarding the market players’ strategy and their geographical presence. The data is available for the period 2020 to 2029.

Competitive Landscape and Chile Gastric Cancer Treatment Market Share Analysis

Chile Gastric cancer treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, and technology lifeline curve. The above data points provided are only related to the companies’ focus related to the Chile gastric cancer treatment market

Some of the major companies, which are dealing in the Chile gastric cancer treatment market are Pfizer Inc., Merck KGaA, Celnova Pharma, Teva Pharmaceutical Industries Limited, AstraZenaca, Bristol-Myers Squibb Company, Sanofi, Laboratorio Varifarma S.A. , Tecnofarma SA., F. Hoffmann-La Roche Ltd., Biotoscana Group, Megalabs Chile SA among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Various contracts and agreements are also initiated by the companies worldwide which are further accelerating the Chile gastric cancer treatment market growth.

For instance,

  • In May 2020, Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA® (ramucirumab injection, 10 mg/mL solution), in combination with erlotinib, for the first-line treatment of people with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. With this approval, CYRAMZA has now received six FDA approvals to treat certain types of lung, liver, stomach and colorectal cancers. This new drug approval of the company has increased its sales and demand in the market leading to increased sales in the future.
  • In November 2019, Pfizer, Inc. announced that its division named Upjohn is combined with Mylan N.V. and formed a new company named Viatris. This combination of the company's business division with Mylan N.V. has increased its product portfolio, leading to increased demand for its product in the market

Customization Available: Chile Gastric Cancer Treatment Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.


SKU-

TABLE 1 CHILE GASTRIC CANCER TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 2 CHILE GASTRIC CANCER TREATMENT MARKET, BY STAGES, 2020-2029 (USD MILLION)

TABLE 3 CHILE GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 4 CHILE CHEMOTHERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 5 CHILE TARGETED THERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 6 CHILE MONOCLONAL ANTIBODY THERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 7 CHILE MULTIKINASE INHIBITORS IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 8 CHILE GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 9 CHILE PARENTERAL IN GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 10 CHILE ORAL IN GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 11 CHILE GASTRIC CANCER TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 12 CHILE GASTRIC CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions

Slides Slides Slides Slides Slides Slides